Lina E Aguirre1,2, Georgia Colleluori3,4, David Robbins1,2, Richard Dorin1,2, Vallabh O Shah1,2, Rui Chen3,4, Irum Zeb Jan1, Clifford Qualls1,2,5, Dennis T Villareal3,4, Reina Armamento-Villareal6,7. 1. New Mexico VA Health Care System, Albuquerque, NM, USA. 2. University of New Mexico School of Medicine, Albuquerque, NM, USA. 3. Baylor College of Medicine, Houston, TX, USA. 4. Michael E. DeBakey VA Medical Center, Houston, TX, USA. 5. Biomedical Research Institute of New Mexico, Albuquerque, NM, USA. 6. Baylor College of Medicine, Houston, TX, USA. reina.villareal@bcm.edu. 7. Michael E. DeBakey VA Medical Center, Houston, TX, USA. reina.villareal@bcm.edu.
Abstract
PURPOSE: To evaluate the influence of single nucleotide polymorphisms (SNPs) of CYP19A1 on the response and susceptibility to side effects from testosterone therapy. This is a prospective, single-arm study of men with low-morning serum testosterone (<10.68 nmol/l) administered testosterone cypionate 200 mg intramuscularly every 2 weeks for 18 months. METHODS: We measured areal bone mineral density (aBMD) and body composition by dual energy X-ray absorptiometry, tibial volumetric BMD and geometry by peripheral quantitative computer tomography, bone turnover markers by enzyme-linked immunosorbent assay, testosterone, and estradiol by liquid-chromatography/mass-spectroscopy, genotyping by microarray, CYP19A1 expression by quantitative polymerase chain reaction, hematocrit and prostate-specific antigen (PSA). RESULTS: We enrolled 105 men (40-74-years-old). SNPs rs1062033 and rs700518 were associated with significant differences in outcomes at 18 months. The GG genotype in rs1062033 had significant increase in whole body aBMD, but had significant decrease in tibial bone size compared to the CG and CC genotypes. Body composition analysis showed that the CC genotype of rs1062033, and the AA genotype of rs700518, had significant increase in total lean and appendicular lean mass compared to CG and GG, and AG and GG, respectively. The GG genotype of rs700518 had significant increase in PSA (GG = 105.8 ± 23.3% vs. AG + AA = 53.4 ± 11.3%, p = 0.046) while hematocrit changes were comparable among genotypes. CYP19A1 expression was highest in GG genotype in both SNPs. CONCLUSIONS: For the first time, we demonstrated that CYP19A1 SNPs influence response to testosterone therapy in hypogonadal men, highlighting the importance of genetic profiling in therapeutics even for common clinical conditions.
PURPOSE: To evaluate the influence of single nucleotide polymorphisms (SNPs) of CYP19A1 on the response and susceptibility to side effects from testosterone therapy. This is a prospective, single-arm study of men with low-morning serum testosterone (<10.68 nmol/l) administered testosterone cypionate 200 mg intramuscularly every 2 weeks for 18 months. METHODS: We measured areal bone mineral density (aBMD) and body composition by dual energy X-ray absorptiometry, tibial volumetric BMD and geometry by peripheral quantitative computer tomography, bone turnover markers by enzyme-linked immunosorbent assay, testosterone, and estradiol by liquid-chromatography/mass-spectroscopy, genotyping by microarray, CYP19A1 expression by quantitative polymerase chain reaction, hematocrit and prostate-specific antigen (PSA). RESULTS: We enrolled 105 men (40-74-years-old). SNPs rs1062033 and rs700518 were associated with significant differences in outcomes at 18 months. The GG genotype in rs1062033 had significant increase in whole body aBMD, but had significant decrease in tibial bone size compared to the CG and CC genotypes. Body composition analysis showed that the CC genotype of rs1062033, and the AA genotype of rs700518, had significant increase in total lean and appendicular lean mass compared to CG and GG, and AG and GG, respectively. The GG genotype of rs700518 had significant increase in PSA (GG = 105.8 ± 23.3% vs. AG + AA = 53.4 ± 11.3%, p = 0.046) while hematocrit changes were comparable among genotypes. CYP19A1 expression was highest in GG genotype in both SNPs. CONCLUSIONS: For the first time, we demonstrated that CYP19A1 SNPs influence response to testosterone therapy in hypogonadal men, highlighting the importance of genetic profiling in therapeutics even for common clinical conditions.
Entities:
Keywords:
Aromatase; Body composition; Bone mineral density; CYP19A1; Testosterone
Authors: E Barrett-Connor; J E Mueller; D G von Mühlen; G A Laughlin; D L Schneider; D J Sartoris Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958
Authors: Shalender Bhasin; Glenn R Cunningham; Frances J Hayes; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2010-06 Impact factor: 5.958
Authors: Li Tang; Mary E Platek; Song Yao; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Yue Wu; Elizabeth A Platz; Marian L Neuhouser; Frank Z Stanczyk; Juergen K V Reichardt; Regina M Santella; Ann Hsing; William D Figg; Scott M Lippman; Ian M Thompson; Christine B Ambrosone Journal: Carcinogenesis Date: 2018-02-09 Impact factor: 4.944
Authors: Peter J Snyder; Shalender Bhasin; Glenn R Cunningham; Alvin M Matsumoto; Alisa J Stephens-Shields; Jane A Cauley; Thomas M Gill; Elizabeth Barrett-Connor; Ronald S Swerdloff; Christina Wang; Kristine E Ensrud; Cora E Lewis; John T Farrar; David Cella; Raymond C Rosen; Marco Pahor; Jill P Crandall; Mark E Molitch; Denise Cifelli; Darlene Dougar; Laura Fluharty; Susan M Resnick; Thomas W Storer; Stephen Anton; Shehzad Basaria; Susan J Diem; Xiaoling Hou; Emile R Mohler; J Kellogg Parsons; Nanette K Wenger; Bret Zeldow; J Richard Landis; Susan S Ellenberg Journal: N Engl J Med Date: 2016-02-18 Impact factor: 91.245
Authors: Anna L Eriksson; Mattias Lorentzon; Liesbeth Vandenput; Fernand Labrie; Marie Lindersson; Ann-Christine Syvänen; Eric S Orwoll; Steven R Cummings; Joseph M Zmuda; Osten Ljunggren; Magnus K Karlsson; Dan Mellström; Claes Ohlsson Journal: J Clin Endocrinol Metab Date: 2008-12-30 Impact factor: 5.958
Authors: Izabela Uzar; Anna Bogacz; Elżbieta Sowińska-Przepiera; Krzysztof Piątek; Filip Przerwa; Marlena Wolek; Bogusław Czerny Journal: J Clin Med Date: 2022-06-20 Impact factor: 4.964